Paxillin Antibody (LD4 sAB) [FITC]
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-81063F
Recombinant Monoclonal Antibody
Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
Human
Applications
ELISA, Immunocytochemistry/ Immunofluorescence, Western Blot
Label
FITC (Excitation = 495 nm, Emission = 519 nm)
Antibody Source
Recombinant Monoclonal Rabbit IgG Kappa Clone # LD4 sAB
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
Peptide corresponding to human paxillin-LD4 motif (residues 260-278) fused to MBP; peptide sequence: WGGSATRELDELMASLSD.
Specificity
The antibody binds specifically to the LD-4 motif of human Paxillin with a Kd of 6 nM.
Clonality
Monoclonal
Host
Rabbit
Isotype
IgG Kappa
Applications for Paxillin Antibody (LD4 sAB) [FITC]
Application
Recommended Usage
ELISA
Optimal dilutions of this antibody should be experimentally determined.
Immunocytochemistry/ Immunofluorescence
Optimal dilutions of this antibody should be experimentally determined.
Western Blot
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
PBS
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: Paxillin
Alternate Names
PXN
Gene Symbol
PXN
Additional Paxillin Products
Product Documents for Paxillin Antibody (LD4 sAB) [FITC]
Product Specific Notices for Paxillin Antibody (LD4 sAB) [FITC]
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...